Loading...
Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes
BACKGROUND: Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Inflammation or insulin resistance might be pathological mediators of cardiovascular events in patients with type 2 diabetes. METHODS: Whether omarigliptin has an...
Na minha lista:
| Udgivet i: | Diabetol Metab Syndr |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7092436/ https://ncbi.nlm.nih.gov/pubmed/32211075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-020-00533-3 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|